Webinar

Switching to Biosimilar Denosumab: Patient Satisfaction and Implications for Clinical Practice

Name: WEBINAR – Switching to Biosimilar Denosumab: Patient Satisfaction and Implications for Clinical Practice
Start: 2026-10-22T12:00:00-04:00
End: 2026-10-22T13:00:00-04:00
Location: Zoom

The introduction of biosimilar denosumab is creating new opportunities, and new questions, for people living with osteoporosis and the healthcare professionals who provide their care.

Join Dr. Aliya Khan, Clinical Professor of Medicine, Division of Endocrinology and Geriatrics, Director of the Calcium Disorders Clinic, and Director of the Fellowship in Metabolic Bone Disease at McMaster University, and Dr. Famida Jiwa, President and CEO, Osteoporosis Canada for a practical discussion of new Canadian real-world evidence on the patient experience of switching from reference denosumab to biosimilar denosumab. The speakers will explore what the research tells us about patient satisfaction, communication, treatment confidence, affordability and access, and what these findings mean in everyday clinical practice.

The webinar will highlight the importance of clear communication and shared understanding when treatment changes occur, while addressing the questions that matter most to patients and healthcare providers.

Webinar Details

Date:
Thursday, October 22, 2026

Time:

12:00 noon – 1:00 pm ET

Register

Register in advance

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone

Address(Required)

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

How did you hear about the webinar?

If you would like to submit a question in advance, please submit below. We will do our best to address all questions during the webinar.

Presenters

Dr. Aliya Khan

MD, FRCPC, FACP, FACE

Dr. Aliya Khan is a Clinical Professor of Medicine, Division of Endocrinology and Geriatrics, Director of the Calcium Disorders Clinic, and Director of the Fellowship in Metabolic Bone Disease at McMaster University. She graduated from the University of Ottawa Medical School with honors. She trained in Internal Medicine, Geriatric Medicine and Endocrinology and completed a fellowship in Metabolic Bone Disease at the University of Toronto. She has published over 400 scientific papers and numerous chapters and books on osteoporosis and parathyroid disease.

She led the development of global guidelines for parathyroid disease, osteonecrosis of the jaw, new diagnostic criteria for hypophosphatasia, treatment guidelines for X-linked hypophosphatemia in addition to osteoporosis guidelines. She is the co-chair of the International Working Group developing best practice recommendations on bone mineral density reporting supported. She is a leading clinician researcher and is the principle investigator evaluating novel therapies for parathyroid disease including PTH , PTH analogues as well PTH1receptor agonists for hypoparathyroidism.

She has received numerous international awards for outstanding contributions to Medicine including the Queen’s Diamond Jubilee Medal, International Osteoporosis Foundation award, Osteoporosis Canada Lindy Fraser award, Woman Physician of the Year Award by the American College of Physicians, Canadian Society of Endocrinology and Metabolism Dr. Jacques Genest Lecture Award. ORTOMED Medal from the Italian Society of Orthopedics and Medicine, King Charles Coronation medal and 2025 American Association of Clinical Endocrinologists Outstanding International Clinician award. She is recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape.

Dr. Famida Jiwa

President and CEO, Osteoporosis Canada

Dr. Jiwa is the President and CEO of Osteoporosis Canada, and has been with the organization since 2006. Prior to joining Osteoporosis Canada, Dr. Jiwa was the former Provincial Osteoporosis Co-ordinator, employed by the Ontario Ministry of Health and Long Term Care and charged with rolling out all aspects of the $5 million annual Ontario Osteoporosis Strategy. Prior to this and after leaving her private practice in Orlando, Florida, Dr. Jiwa was a Program Consultant for the Acute Services Division of the Ministry of Health, where she played a significant role in project planning, implementation and evaluation of a number of provincial health initiatives, including chronic kidney disease, asthma and age-related macular degeneration.

In 2020 Dr. Jiwa was elected to the Board of Directors of the International Osteoporosis Foundation, representing North America, for a term of 4 years. She also serves as the chair of the Patient Societies Subcommittee of the Committee of National Societies (CNS) of the International Osteoporosis Foundation (IOF). In 2020, Dr. Jiwa was awarded the CNS Medal from the International Osteoporosis Foundation. In 2016, she was awarded the President’s Award from the International Osteoporosis Foundation. She is also the recipient of the Queen Elizabeth II Diamond Jubilee Medal. Dr. Jiwa has also attained the designation of Certified Health Executive from the Canadian College of Health Leaders, and in 2017 she completed the Strategic Perspectives in Nonprofit Management program at Harvard Business School.

She holds a Masters Degree in Health Administration from the Department of Health Policy, Management and Evaluation from the University of Toronto, a Doctorate of Chiropractic from the Canadian Memorial Chiropractic College in Toronto, as well as an Honours Bachelor of Science, Genetics and Psychology from the University of Toronto.